BRPI1006438A2 - terapia adjuvante de cancer - Google Patents

terapia adjuvante de cancer

Info

Publication number
BRPI1006438A2
BRPI1006438A2 BRPI1006438A BRPI1006438A BRPI1006438A2 BR PI1006438 A2 BRPI1006438 A2 BR PI1006438A2 BR PI1006438 A BRPI1006438 A BR PI1006438A BR PI1006438 A BRPI1006438 A BR PI1006438A BR PI1006438 A2 BRPI1006438 A2 BR PI1006438A2
Authority
BR
Brazil
Prior art keywords
cancer therapy
adjuvant cancer
adjuvant
therapy
cancer
Prior art date
Application number
BRPI1006438A
Other languages
English (en)
Inventor
Eric Hedrick
Gwendolyn Fyfe
Norman Wolmark
Robert D Mass
Original Assignee
Genentech Inc
Nsabp Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Nsabp Foundation Inc filed Critical Genentech Inc
Publication of BRPI1006438A2 publication Critical patent/BRPI1006438A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Fertilizers (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BRPI1006438A 2009-04-20 2010-04-20 terapia adjuvante de cancer BRPI1006438A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17100809P 2009-04-20 2009-04-20
US17131809P 2009-04-21 2009-04-21
US18119509P 2009-05-26 2009-05-26
PCT/US2010/031740 WO2010123891A1 (en) 2009-04-20 2010-04-20 Adjuvant cancer therapy

Publications (1)

Publication Number Publication Date
BRPI1006438A2 true BRPI1006438A2 (pt) 2016-09-27

Family

ID=42235124

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1006438A BRPI1006438A2 (pt) 2009-04-20 2010-04-20 terapia adjuvante de cancer

Country Status (19)

Country Link
US (1) US20100266589A1 (pt)
EP (1) EP2421558A1 (pt)
JP (1) JP2012524083A (pt)
KR (1) KR20120096401A (pt)
CN (1) CN102458467A (pt)
AR (1) AR076344A1 (pt)
AU (1) AU2010239368A1 (pt)
BR (1) BRPI1006438A2 (pt)
CA (1) CA2759030A1 (pt)
CL (1) CL2011002610A1 (pt)
CO (1) CO6450651A2 (pt)
CR (1) CR20110553A (pt)
IL (1) IL215764A0 (pt)
MA (1) MA33323B1 (pt)
MX (1) MX2011010955A (pt)
RU (1) RU2011147051A (pt)
SG (1) SG175289A1 (pt)
TW (1) TW201106969A (pt)
WO (1) WO2010123891A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2664738C (en) 2006-09-29 2017-03-07 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US8883145B2 (en) 2009-10-16 2014-11-11 Oncomed Pharmaceuticals, Inc. Methods of treatment with DLL4 antagonists and an anti-hypertensive agent
US11536713B2 (en) 2009-12-25 2022-12-27 Chugai Seiyaku Kabushiki Kaisha Method for searching and screening for target of anti-cancer agent using non-human animal model having NOG established cancer cell line transplanted therein
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
CN103328626B (zh) 2010-10-06 2017-02-08 中外制药株式会社 癌干细胞群及其制备方法
EP2749641B1 (en) 2011-09-07 2021-06-02 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell isolation
JP6170496B2 (ja) 2011-09-23 2017-07-26 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｖｅｇｆ／ｄｌｌ４結合剤およびその使用
US20140302511A1 (en) 2011-10-28 2014-10-09 Pharmalogicals Research Pte. Ltd. Cancer stem cell-specific molecule
RU2689760C2 (ru) * 2012-05-31 2019-05-30 Дженентек, Инк. Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов
CA2879570A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
SG11201500903XA (en) * 2012-08-07 2015-03-30 Genentech Inc Combination therapy for the treatment of glioblastoma
JP6371294B2 (ja) 2012-10-31 2018-08-08 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｄｌｌ４アンタゴニストによる処置の方法およびモニタリング
PE20151604A1 (es) 2012-11-02 2015-11-04 Pharmacyclics Llc Terapia adyuvante con inhibidores de quinasa de la familia tec
US20140348821A1 (en) * 2013-05-24 2014-11-27 Nsabp Foundation, Inc. Defective Mismatch Repair and Benefit from Bevacizumab for Colon Cancer
US10456470B2 (en) 2013-08-30 2019-10-29 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
US10617755B2 (en) 2013-08-30 2020-04-14 Genentech, Inc. Combination therapy for the treatment of glioblastoma
EP3119910A4 (en) 2014-03-20 2018-02-21 Pharmacyclics LLC Phospholipase c gamma 2 and resistance associated mutations
WO2016011052A1 (en) 2014-07-14 2016-01-21 Genentech, Inc. Diagnostic methods and compositions for treatment of glioblastoma
WO2016070051A2 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
WO2017042318A1 (en) * 2015-09-10 2017-03-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Chemerin polypeptide for the treatment of cancer-induced cachexia
EP3353204B1 (en) 2015-09-23 2023-10-18 Mereo BioPharma 5, Inc. Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) * 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5730977A (en) * 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
KR100870353B1 (ko) * 1997-04-07 2008-11-25 제넨테크, 인크. 항-ｖｅｇｆ 항체
US6884879B1 (en) * 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) * 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6703020B1 (en) * 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
KR20160014775A (ko) * 2003-05-30 2016-02-11 제넨테크, 인크. 항-ｖｅｇｆ 항체를 사용한 치료
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) * 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
US20060009360A1 (en) * 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
HUE029445T2 (en) * 2006-12-19 2017-02-28 Genentech Inc VEGF-specific antagonists for adjuvant and neoadjuvant therapy and treatment of early-stage tumors
JP2010518013A (ja) * 2007-02-01 2010-05-27 ジェネンテック， インコーポレイテッド 血管形成阻害剤を含む組み合わせ治療の方法
AR069501A1 (es) * 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)

Also Published As

Publication number Publication date
CN102458467A (zh) 2012-05-16
WO2010123891A1 (en) 2010-10-28
KR20120096401A (ko) 2012-08-30
IL215764A0 (en) 2012-01-31
RU2011147051A (ru) 2013-05-27
CR20110553A (es) 2012-01-23
CO6450651A2 (es) 2012-05-31
MA33323B1 (fr) 2012-06-01
SG175289A1 (en) 2011-11-28
US20100266589A1 (en) 2010-10-21
AR076344A1 (es) 2011-06-01
JP2012524083A (ja) 2012-10-11
AU2010239368A1 (en) 2011-11-10
TW201106969A (en) 2011-03-01
EP2421558A1 (en) 2012-02-29
CL2011002610A1 (es) 2012-04-09
CA2759030A1 (en) 2010-10-28
MX2011010955A (es) 2012-04-02

Similar Documents

Publication Publication Date Title
BRPI1006438A2 (pt) terapia adjuvante de cancer
BR112012005594A2 (pt) tratamento de câncer
EP2448492A4 (en) IMAGE-GUIDED RADIOTHERAPY
DE602009000539D1 (de) Strahlentherapiegerät
LT3192529T (lt) Amatoksinu užtaisyti terapiniai su ląstelės paviršiumi susirišantys komponentai, sukonstruoti navikų terapijai
BR112012002797A2 (pt) tratamento de câncer de próstata
EP2405749A4 (en) THERAPY TO LOW FREQUENCY GLATIRAMERATE ACETATE
ATE526024T1 (de) Fluvoxamin vermeidende pirfenidontheraphy
LT2707030T (lt) Vėžio gydymas
HUE046667T2 (hu) Rák kombinatív kezelése
BRPI1013618A2 (pt) pirimidinas substituídas para o tratamento de câncer
BRPI1010874A8 (pt) composição para o tratamento de câncer de próstata
BR112013011659A2 (pt) métodos de tratamento do câncer
BRPI1007995A2 (pt) orto-aminoamidas para o tratamento de cãncer.
BRPI0922884A2 (pt) compostos para tratamento de câncer
IL222958A0 (en) Cancer treatment
GB201003293D0 (en) Cancer vaccine
EP2346531A4 (en) ANTITUMOR VACCINE
HUE038563T2 (hu) Rák kezelési eljárás
GB2471750B (en) Radiation therapy device
PL2467140T3 (pl) Lapatynib do leczenia raka
BRPI0918508A2 (pt) orto-aminoanilidas para o tratamento de câncer
EP2585115A4 (en) Cancer therapy
BRPI1013903A2 (pt) tratamentos terapêuticos utilizando centaquina
GB0910751D0 (en) Prostate cancer vaccine

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]